Header Bar
  eNewsLine - Reporting our progress in the battle against leukemia, lymphoma, Hodgkin's disease and myeloma  

 
OCTOBER 2009
888.HELP.LLS Donate Now Forward to a Friend
 

Scott Hamilton AWARENESS

LLS is a Partner in a Thanksgiving Day TV Special to Raise Cancer Awareness
READ MORE

Andrea Pitta

PATIENT SERVICES

Andrea Pitta, A Great Volunteer in the San
Diego/Hawaii Chapter

READ MORE

CMO Commentary: Chief Medical Officer Barton Kamen, M.D., Ph.D., Talks About AML  READ MORE

AML & ALL Teleconferences in November 
READ MORE

Co-Pay Assistance Program Broadens Funding
READ MORE


FUNDRAISING UPDATES

Team In Training - Featuring El Tour de Tucson and The Walt Disney World Marathon and Half Marathon Weekend  READ MORE

Former Vice President Al Gore was the Guest Speaker at San Francisco Leukemia Cup Regatta  READ MORE

School & Youth - LLS Presents  Chairman's Citation Award to Indianapolis Colts Gary Brackett, for His Support of Pennies
for Patients
  READ MORE

A Massachusetts Chapter Hike Leader, Cellist Plans a 50-State Tour to Benefit LLS  READ MORE

Cards for a Cause Benefit LLS READ MORE

Use Appreciated Stock for Year-End Giving  READ MORE

RESEARCH

Chief Scientific Officer Louis DeGennaro, Ph.D., Participates in Conferences to Advance Therapy Acceleration Program  READ MORE

Q&A - Pamela Becker, M.D., Ph.D, of University of Washington Discusses her Research Studying the Role of Cell Adhesion in Chemotherapy Resistance  READ MORE

ADVOCACY

Senior Vice President of Public Policy George Dahlman Elected Co-Chair of Alliance for Childhood Cancer  READ MORE

FROM THE LLS BLOG  READ MORE



 

News Room Image

PRESS RELEASES

Visit our Web site regularly to read the latest LLS press releases.

RSS Icon NEWS FEEDS & PODCASTS

Constant dripping hollows out a stone. Lucretius

AWARENESS

Scott HamiltonStars Take the Ice for TV Special to Raise Cancer Awareness

Olympic gold medalist Scott Hamilton will skate on TV for the first time since battling a brain tumor and testicular cancer, joining fellow Olympian and cancer survivor Dorothy Hamill for a Thanksgiving Day special intended to inspire viewers to triumph over illness.

The Leukemia & Lymphoma Society (LLS) is one of the advocacy partners of the program, "Kaleidoscope," airing 4-5:30 p.m. EST Nov. 26 on Fox, along with 10 other organizations. The opportunity to be part of this program was brought to LLS by a researcher whose patient is the executive producer of the show. The show is designed to raise awareness and recognize the role that women play in the battle against cancer - as patients, caregivers and advocates. The mission of this program is to address issues surrounding women and cancer by helping educate women to be proactive with their health and by honoring all cancer survivors. 

The program will also will feature 1992 Olympic figure skating champion Kristi Yamaguchi and two-time medalist Nancy Kerrigan, along with Olympic hopefuls Johnny Weir and Rachael Flatt. Hamill, the 1976 gold medalist, will skate to a song performed by Olivia Newton-John. Both women were diagnosed with breast cancer.

"We're trying to get the word out in a way that won't make people turn the channel the second they hear the "C" word," says Hamilton, winner of the 1984 Olympic gold medal and a four-time world champion. "It's about embracing life and moving forward and knowing you can get back to your better self, your best self, even after something as invasive and as challenging as a cancer diagnosis and treatment."


Back to the top

PATIENT SERVICES

San Diego-Hawaii Chapter Volunteer Wears Many Hats Andrea Pitta

Learning that you have cancer is frightening and overwhelming. Patients and their families need help to cope with the physical, emotional and financial challenges that come with a cancer diagnosis.

As a volunteer patient navigation coordinator for the San Diego-Hawaii Chapter of The Leukemia & Lymphoma Society (LLS), Andrea Pitta, a homemaker and mother of two, works with Patient Services Manager Jose Montes, to identify patients who need enhanced services, and helps them get the support and resources they need to make their way through the complicated journey from diagnosis through treatment and survivorship.  

"It's a very delicate process and I want to ensure that patients know LLS is here to provide resources to help make that aspect of their diagnosis a little easier," says Pitta.

Pitta helped create a welcome packet with disease-specific information, along with information about local services and upcoming events that might be helpful for the patient.

One of "Sophia's Hats" But navigation coordinator is only one of the many roles that Pitta plays as a volunteer for the chapter. She also created an innovative program for the chapter called "Sophia's Hats," named after her grandmother, Sophia May, who lost her 15-year battle with leukemia in 2008. The program is completely run by volunteers who create hats for patients who have lost their hair from chemotherapy.

"One morning after talking with patients who had lost or were losing their hair from treatment I thought it would be a great idea to provide them with something to make them look good and feel good about themselves," Pitta said.

Pitta, who also coordinates the chapter's annual Light The Night® Walk "Remembrance Ceremony," providing an opportunity for family and friends to honor their loved ones lost to a blood cancer, is one great example of how to volunteer with LLS. Here is more information about volunteering
.


Back to the top


Barton Kamen, M.D., Ph.D.

CMO Commentary: Acute Myelogenous Leukemia:  We Are
Making Progress!

Acute Myelogenous Leukemia (AML) remains one of the most difficult of the hematological malignancies. For the past three decades, the most widely used initial induction treatment for AML patients has been a combination simply referred to as "7 & 3." The protocol is generally seven days of ARA-C (cytarabine) and three days of an anthracycline, most often daunorubicin, though there are several variations on the dosages and durations. These treatments often result in four to six weeks in the hospital, and then yet more treatment.   

At the end of September, two articles and an editorial in the New England Journal of Medicine suggested that some patients would do better if they received twice the usual dose of the daunorubicin. Not everyone would benefit, such as those with adverse cytogenetics or a mutation of the FLT3 gene. But the studies showed that, at least in the short term, toxicity was manageable so some patients could benefit.  

Why do I sound guardedly optimistic that after 30 plus years we can double the dose of a drug that was toxic and possibly help some people? I do not think that the treatment has really changed that much. The supportive care (e.g. transfusion, antibiotics, parenteral nutrition and intensive care units) is better. My hopefulness relates to our previous discussion of the
3 Ts of treatment last month. In this case the Typing is the clue. When "7&3" was developed, all patients diagnosed with AML were treated the same. Today, if you are diagnosed with AML, we talk about eight different classifications of the disease, M0 through M7, based on the type of cell from which the leukemia developed and how mature the cells are.  

Promyelocytic (M3) AML has proven very susceptible to retinoic acid (vitamin A) and arsenic Trioxide (yes a vitamin and arsenic). Moreover, as we identify more molecular biological/chromosomal changes we are learning more about who will be more likely to be cured and who will be resistant to treatment. For example, patients with "Core Binding Factor" (CBF) AML have a more promising prognosis, whereas those with a mutation in FLT3 (FMS like kinase) still pose more of a challenge to treat.  

So what does this mean for patients diagnosed with AML? With an overall survival rate of 50%, AML remains one of the more challenging hematologic malignancies.  However, for those with a "better prognosis" AML, the standard therapy, perhaps now with a double dose of the daunorubicin, might be all that is required for the best risk benefit ratio:  the highest cure rate with minimal toxicity. The lesson is that AML is very many different diseases and patients need to be treated at centers that are prepared to do all the diagnostic tests in real time in order to plan the optimal therapy. For many AML patients, the standard of care remains a clinical trial where novel protocols are being tested. A clinical trial still affords the best path to success in AML.

Information for Newly Diagnosed Patients
People who have recently received a diagnosis of a blood cancer often have questions about the disease, the prognosis and the treatments available.  It is important to learn about the disease, but also to learn about insurance coverage, healthcare facilities and how to obtain support. Specific questions may also be answered by information specialists at The Leukemia & Lymphoma Society's
Information Resource Center. The center is open every business day, 9 a.m. to 6 p.m. ET, at (800) 955-4572.

Additional Resources on AML:
Acute Myelogenous Leukemia (AML) (PS32)
Acute Myelogenous Leukemia: A Guide for Patients and Caregivers (PS66)
Understanding Clinical Trials for Blood Cancers (PS12) 

The Leukemia & Lymphoma Society Clinical Trial Service -TrialCheck®
Easily find clinical trials near you through the LLS-supported
TrialCheck® website, a clinical trial search service that offers patients and caregivers immediate access to listings of all leukemia, lymphoma and Myeloma and related blood cancer clinical trials. Answer just a few simple questions and a list of available clinical trials related to your cancer will appear in an easy to read list of search results.

Back to the top



Upcoming Telephone/Webcast Education Programs


The Pediatric Treatment Approach to Adult Acute Lymphocytic Leukemia: Perspectives
for Oncology Nurses

Date: Thursday, November 19, 2009Woman on Phone
Time:  12:00 PM to 1:30 PM Eastern Time  

This nursing program will feature Barton A. Kamen, M.D., Ph.D., chief medical officer of The Leukemia & Lymphoma Society, Professor of Pediatrics and Pharmacology, The Cancer Institute of New Jersey, UMDNJ - Robert Wood Johnson Medical School, New Brunswick, NJ and Katherine A. Breitenbach, B.A., R.N., Clinical Research Nurse Section of Hematology/Oncology, University of Chicago Medical Center, Chicago. This continuing education program is supported by a grant from Enzon Pharmaceuticals, Inc.                   


Understanding AML: From Diagnosis to Treatment

Date:  Tuesday, November 24, 2009
Time: 12:00-1:00pm Eastern Time

This program will feature Elihu H.Estey, M.D., Professor of Medicine, Division of Hematology, University of Washington School of Medicine, Member, Fred Hutchinson Cancer Research Center Seattle, Adjunct Professor, The University of Texas, M.D. Anderson Cancer Center Houston. This continuing education program is supported by a grant from Cephalon Oncology.

NEW OPTION
You now have the option of listening to the program from your computer (webcast). When you register for the program, you will be asked if you want to participate by phone or via webcast. If you choose webcast, you will be sent an e-mail providing you with a URL link for you to click on the day of the program.

Featured Webclip Program  
 
Financial Health Matters

This program features interviews with Anita Welborn, LMSW of The Leukemia & Lymphoma Society,
Dana Krohn of the Medicare Rights Center and David Landay, Esq. of Survivorship A to Z and focuses on the financial impact a cancer diagnosis can have, with information on insurance programs and resources for support.
This free educational program is for patients, caregivers and healthcare professionals. This is a complimentary online continuing education activity.  


Back to the top

 



Co-Pay Image Co-Pay Assistance Program Broadens Funding
Qualified patients with chronic myelogenous leukemia and myeloma can now receive up to $5,000 in assistance from The Leukemia & Lymphoma Society's (LLS) Co-Pay Assistance Program. The aid helps offset prescription drug co-pays and other insurance-related expenses according to disease diagnosis. For more information, visit www.LLS.org/copay
or call (877) 557-2672.
 
The LLS Co-Pay Assistance program is pleased to announce a new tool to help patients and providers submit online applications quickly and easily. The Co-Pay Assistance program provides financial assistance for health insurance payments and blood cancer treatment co-pay obligations to qualified patients. For more information, visit www.LLS.org/copay
or call (877) 557-2672.


Back to the top

FUNDRAISING UPDATES

Cycling in the Desert and a Trip to the Magic Kingdom Team in Training® Logo

Gene Espinosa, 47, of Tucson, has overcome great odds to become a long-distance cyclist. Espinosa was diagnosed in 1978 with lymphoma at a time when there were few effective treatments for the disease. Since that time, researchers, many funded by The Leukemia & Lymphoma Society (LLS), have advanced therapies that have dramatically improved the survival rates for this blood cancer.
 
Gene Espinosa"Back then, the cancer was supposed to kill you. If it didn't the chemicals usually would," recalls Espinosa, who said he lost to cancer many friends who he met during his stays at the hospital. But Espinosa did survive. And now he is dedicated to helping find cures for patients with lymphoma and other blood cancers.

In 2005 Espinosa signed up for El Tour de Tucson, a century ride in the Sonora Desert, as a member of LLS's Team In Training (TNT). He has participated in El Tour every year since then and will be among approximately 300 TNT participants taking part in this year's El Tour de Tucson on November 21, 2009. Since 1996, TNT has sent 7,200 participants to El Tour, raising more than $18 million to support blood cancer research and patient services.

Meanwhile, TNT participants are already gearing up for another exciting event weekend at the Walt Disney World Marathon January 9-10, 2010.

One of those participants is Megan Lott, of Ft. Pierce, Fla., who ran the race last year in honor of her cousin, Shana Pardue, a lymphoma survivor, whose cancer was in remission.  Megan raised enough funds so that both she and her cousin could be a part of the LLS Palm Beach chapter team last year. This season Lott has rejoined the team as an alumna, but recently learned that her cousin's lymphoma had returned. Pardue had begun training as a member of Virtual TNT, but has had to put that on hold because of the recurrence of her lymphoma.

"Now I am more motivated than ever to train and raise funds to support LLS's mission," says Lott.  In fact Lott has joined the chapter's "Marathon Maniac" program in which she will participate in all three events offered by the chapter this winter, and will raise over $5,000 in an effort to find a cure.

TNT is currently recruiting for its spring season, with events including the Disney's Princess Half Marathon, the Mardi Gras Marathon & 1/2  in New Orleans, and the Marathon de Paris. To learn more please visit www.teamintraining.org
.

Back to the top



Honorary Chair Tom Perkins, Honorary Skipper Campbell Nolan and Vice President Al GoreGreater San Francisco Leukemia Cup Regatta Makes a
Big Splash


For the third year in a row, the Greater San Francisco Chapter's Leukemia Cup Regatta raised more than any other Leukemia Cup totaling over $655,000 to support blood cancer research and patient services.

More than 100 boats, two days of racing, and a fabulous VIP dinner, with special guest former Vice President Al Gore, made for an exciting weekend.

"We appreciate the support of our honorary chairman, Tom Perkins. He has been a key part of the Leukemia Cup for the last three years, bringing his 88 meter yacht, the Maltese Falcon, to San Francisco Bay for our event and recruiting our last two keynote speakers, Rupert Murdoch in 2008 and the honorable Al Gore in 2009," said Bill Nolan, Bay Area Chapter Trustee and Co-Chair. "Everyone enjoyed Mr. Gore's discussion this year and, as evidenced by the spirited response from our audience, he made it a truly memorable evening."

The Leukemia Cup Regatta logo Bill Nolan was also the top San Francisco fundraiser. His son, Campbell Nolan, is a leukemia survivor. Bill was aboard the top fundraising boat, Full Throttle, skippered by committee co-chair David Joyner. Co-Chair Ian Charles was also on board.

More than a dozen participants - Ian Charles, Matt Cromar, Kyle Elliott, Erica Embley, Anne Feinberg, David Joyner, Torin Knorr, John McNeill, Suzie Moore, Bill Nolan, Molly Prahl, Bill Smith, and Robin Reynolds qualified for the Fantasy Sail with Leukemia Cup Regatta National Chairman Gary Jobson that took place at the San Francisco Yacht Club October 17. Each of these qualifiers raised more than $8,500 each totaling more than $202,000!  

Click here to learn more about the Leukemia Cup Regatta. 

Back to the top


Colts Defensive Captain Gary Brackett surrounded by honored heroes
LLS Recognizes Indianapolis Colts Defensive Captain
Gary Brackett

In recognition of his strong support for The Leukemia & Lymphoma Society's (LLS) Pennies for Patients® program, the LLS Indiana Chapter last month presented Indianapolis Colts defensive captain Gary Brackett with the Chairman's Citation Award. Brackett accepted the award at a press conference held at the Indiana Farm Bureau Football Center.

 "I'm thankful to LLS, which is a great organization, for giving me this award," Brackett said. "I think of myself of being more than a football player. The victories are great, but to really have lasting impressions on your community and see some of these kids and make an impact on their lives, those are lifetime achievements."

Brackett's older brother, Greg, was diagnosed with leukemia six years ago.  After finding out he was a match, Brackett donated bone marrow to his brother, who subsequently lost his battle to the disease in 2005.  It is for this reason that Brackett got involved with LLS three years ago.

Brackett has been a "truly dedicated supporter of LLS's Pennies for Patients," according to Indiana Chapter Executive Director Amy Kwas. Brackett even made a personal visit to the top two fundraising schools, both of which collected more than $11,000 in 2009.

Pennies for Patients logo Nominations for the LLS Chairman's Citation Award are made by local chapters and presented in a local venue. The award recognizes candidates who have made a significant impact in the quest to find cures. Brackett joins an illustrious group of other outstanding professional athletes to have received the award, including baseball greats Gary Carter, Joe Mel Stottlemyre, Todd Stottlemyre and Frank Thomas, and football stars Dan Marino, Bobby Mitchell, Karl Nelson, Lawrence Taylor and Rod Woodson.

Click here to learn more about Pennies for Patients, a school-based fund raiser in which children collect spare change to support blood cancer research and patient services; and here, to learn about LLS's other School & YouthSM programs.


Back to the top


Liam Abramson 50 Concerts in 50 States to Benefit LLS

A Boston-based cellist, who has also led hikes for The Leukemia & Lymphoma Society's (LLS) Team In Training (TNT) program, has launched an ambitious cross-country project to fight cancer by raising funds and awareness state by state.

Cellist Liam Abramson kicked off his project, 50 Concerts in 50 States ( www.findacurenow.com
), on Oct. 19 with a concert at the Chicago Cultural Center. Abramson has set a goal of donating at least $50,000 to LLS through the 24-month project.  

Abramson, who trained at the Royal College of Music in London and is the recipient of numerous scholarships and awards, has devoted his efforts to raising money for cancer research since losing his best friend to the disease in 2003. Abramson will perform J.S Bach's Suites for Unaccompanied Cello during this tour.

"I'm one of those people who sets the bar high," said Abramson, who has been a hike leader and mentor for TNT. "The one piece of advice I consistently give out is 'raise money by doing something you know how to do.'"

Concerts are currently scheduled for Ann Arbor, Mich. (Oct. 28, 2009); Boulder, Colo.(Nov. 28, 2009); Sacramento, Calif. (Aug 7, 2010), Logan, Utah (2010), Searcy, Ark. (2010) and Boston, Mass.(2010); Please visit www.findacurenow.com
as the schedule will be continually updated.
 

Back to the top



Jessica Lucas with LLS card"Cards for a Cause" Benefits LLS

CardsDirect.com, a custom printed card and stationery company, will be donating proceeds of the sale of a special holiday card this season to The Leukemia & Lymphoma Society (LLS) as part of its "Cards for a Cause" holiday greeting cards program.

CardsDirect launched 'Cards for a Cause' holiday greeting cards program at the HBO Luxury Lounge in honor of the 61st Emmy Awards this year, where a line of exclusive holiday greeting card designs were available for celebrities to select. These cards will be on sale on the CardsDirect website through December 31, 2009, with net proceeds from the sales of these cards going to the celebrity's charity of choice.

LLS Cards for a Cure Jessica Lucas, a star of the show, "Melrose Place," selected LLS.

You can visit http://www.cardsdirect.com/cards-for-a-cause.aspx
, where the card that supports LLS is featured. The card includes Lucas's printed signature and charity logo along with your custom imprinted verse and personalization, all printed on 100% recycled card stock with 100% post-consumer fiber.


Back to the top


Cash Gift Use Stock Market Gains For Charitable Giving

Recent stock market gains are encouraging to some investors following last year's price plunge. But many are more attuned to market uncertainties than in the past and want to protect their gains. One way you can lock in the value of an investment is to use it for year-end giving. 

If you donate appreciated shares that you have owned for a year or more, you can claim a deduction for the stock's full market value regardless of what you actually paid for the investment. Further, you will not owe any capital gains tax on the appreciated amount. 

For example, Lotta Dough purchased stock for $1,000 a few years ago. Today, her investment is worth $5,000.
If she donates the shares to The Leukemia & Lymphoma Society, she is eligible for a $5,000 charitable deduction and she avoids $600 in capital gains tax that would have been due on the increased value had she sold the stock. 

If you want to use appreciated stock for your year-end giving, request transfer instructions and our broker information from Donor Relations: 1-888-773-9958 or click here
.

Back to the top

RESEARCH
Louis DeGennaro, Ph.D.
LLS Therapy Acceleration Program Gains Industry Attention

The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program (TAP) continues to attract the attention of industry leaders in drug development. LLS Chief Scientific Officer Louis DeGennaro, Ph.D., has been invited to several prestigious conferences to participate as a panel member during the month of October.

As a panelist for a discussion entitled "Disease Foundations and Venture Capital: Can the Two "Play in the Same Sandbox?" hosted by MassBio on October 6, DeGennaro joined six others, from Fast Forward, LLC, an initiative to speed delivery of treatment for patients with multiple sclerosis; EMD Serono Inc., a biopharmaceutical company; Juvenile Diabetes Research Foundation; Celetar Pharmaceuticals and Tolerx, a biopharmaceutical company.

The panel addressed ways that disease foundations are investing and how biotech companies are now collaborating with both venture capital and foundations. It became apparent that organizations like LLS conduct a lot of diligence before deciding to fund a company. The panel also addressed ways to work with companies having difficulty achieving critical development milestones. Ultimately the panel concluded that biotech companies can in fact satisfy investors with two different endgames operating on two different timelines to bring new therapies to patients.

On October 28 and 29, DeGennaro will present LLS's progress through TAP at the 8th Annual Bio Investor Forum in San Francisco. The forum will involve more than 110 late stage private and emerging public company presentations, therapeutic panels led by clinical thought leaders, and business roundtables addressing key issues affecting drug development in biotech companies.

"These meetings provide LLS with a great opportunity to talk about ways that we can build partnerships with pharmaceutical and venture capitalists to pool resources and develop drugs that can further LLS's goal of bringing more treatments to blood cancer patients more quickly," said DeGennaro.

Founded in 2007, TAP supports private sector and academic-based projects with the goal of moving more blood cancer therapies into the development pipeline. Click here
to learn more.

Back to the top


Research Q&A: Pamela S. Becker, M.D., Ph.D. Pamela S. Becker, MD, Ph.D.
Associate Professor of Medicine, Division of Hematology
University of Washington School of Medicine
. Recipient of a translational research program grant from The Leukemia & Lymphoma Society (LLS) to study cell adhesion mediated chemotherapy resistance in acute myelogenous leukemia and multiple myeloma

What is the biomedical problem/issue that you are trying to resolve?  
The focus of my research is how adhesion to other cells within the bone marrow enables acute myeloid leukemia cells to resist chemotherapy.
 
What's novel or innovative about your approach?
The novel aspect of our approach is to determine the critical interactions between leukemia stem cells and leukemia-derived bone marrow stroma (supportive cells), then utilize inhibitors of this protective interaction to enhance chemotherapy effect and leukemia cell death.  

How will your work one day help patients?
Inhibitors of adhesion are now being successfully combined with chemotherapy agents in the lab to kill leukemia cells better, and clinical trials are being initiated to test this approach in patients.

Are you close to clinical trials?
Yes, new clinical trials are due to begin this fall, and early trials are in progress.

What other projects are you excited about and believe will benefit patients?
There may be potential for new combinations of different agents that may be more effective, and the potential for new drugs as well.

What are some of your hobbies and non-research interests?
My hobbies are gardening, swimming, and music. I also volunteer for LLS.


Back to the top

ADVOCACY

The Leukemia & Lymphoma Society Takes Leadership Position on the Alliance for Childhood Cancer

The Leukemia & Lymphoma Society (LLS) has taken another step forward in its leadership in the fight against pediatric cancer with the unanimous election of LLS Senior Vice President of Public Policy George Dahlman as the new co-chair of the Alliance for Childhood Cancer.

The Alliance for Childhood Cancer
represents more than twenty national George Dahlman patient advocacy groups and professional medical and scientific organizations. Patient advocates, many of whom are either cancer survivors themselves or are parents of children with cancer, are joined by oncology professionals and others representing the multidisciplinary spectrum of cancer care in a unique alliance that brings concerned parties together to advance the interests of children with cancer.

LLS policy goals mirror much of the Alliance agenda and its leadership will help focus collective attention on key priorities for the pediatric cancer community. Among them are:
  • Pediatric Cancer Research Funding: Last year the Congress passed and the President signed into law the Caroline Pryce Walker Conquer Childhood Cancer Act, providing for enhanced research, public education and a pediatric cancer registry. Funding for the program is now primary goal for the pediatric cancer community.
  • The Childhood Cancer Survivorship Research and Quality of Life Act (H.R.2109) was introduced in the House of Representatives by Jackie Speier (CA) Mary Bono Mack in April 2009. This legislation would improve and enhance cancer survivorship research and programs.
Capitol Image"This election is a great honor by colleagues in the children's cancer family," said Dahlman, "It is my hope to fulfill their confidence by bringing our collective weight to bear in helping address the problems of children with cancer and their families."

Act Now - Urge Your Representative to Co-Sponsor Pediatric Cancer Survivorship Legislation

Back to the top

From the LLS Blog

The Leukemia & Lymphoma Society Blog is an interactive communication resource, updated regularly with news from LLS, as well as guest blog posts from those touched by blood cancer. LLS welcomes your comments on blog posts, as well as feedback to make this a better communication resource for you.

Here's the latest from the LLS blog:

Patient Story: Christen's little miracle of hope


Back to the top




You are currently receiving national news from LLS.  Your local chapter may also produce a local eNewsletter called The Chapter Report.  If you'd like to receive The Chapter Report please contact your local chapter to subscribe. 

Click here to find your chapter's contact information. 

  Supported by an unrestricted educational grant from Cephalon Oncology Allos Therapeutics, Inc

eNEWSLINE is published by The Leukemia & Lymphoma Society®
Home Office | 1311 Mamaroneck Avenue | White Plains, NY 10605
914.949.5213
www.LLS.org

© 2009 The Leukemia & Lymphoma Society
All Rights Reserved

The Leukemia & Lymphoma Society Logo

Donate Now

Participating member of An Alliance of America's Premier Health Charities in the Combined Federal Campaign, the National Coalition for Cancer Research and Blood Cancer Coalition. This publication is designed to provide information in regard to the subject matter covered, and is distributed as a public service by The Leukemia & Lymphoma Society, with the understanding that LLS is not engaged in rendering medical or other professional services.

The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
www.lls.org.

Visit our e-Store & Special Offers page, where you can support businesses that support LLS.

Please remember LLS in your will or as a beneficiary in your retirement plan. For information, call (888) 773-9958.